# Silymarin in COVID-19 Patients Admitted to Hospital With Elevated Liver Enzymes

> **NCT04816682** · PHASE4 · COMPLETED · sponsor: **F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica** · enrollment: 30 (actual)

## Conditions studied

- Covid19
- Liver Diseases

## Interventions

- **DRUG:** Silymarin

## Key facts

- **NCT ID:** NCT04816682
- **Lead sponsor:** F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-17
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04816682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04816682, "Silymarin in COVID-19 Patients Admitted to Hospital With Elevated Liver Enzymes". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04816682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*